

Prof. Sabahattin KAYMAKOĞLU

Personal Information

Email: sabahattin.kaymakoglu@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/926/>

International Researcher IDs

ORCID: 0000-0003-4910-249X

Publons / Web Of Science ResearcherID: AAT-2362-2020

Yoksis Researcher ID: 124147

Education Information

Post Doctorate of Medicine, Istanbul University, Istanbul Medical Faculty, Division Of Medical Sciences , Turkey 1990 - 1992

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Efficacy and Safety of Sofosbuvir and Ledipasvir for Hepatitis C in Kidney Transplant Recipients: A Single-center Retrospective Observational Study.**
Artan A. S., Mirioğlu Ş., İstemihan Z., Aksoy E., Dirim A. B., Çavuş B., Oto Ö. A., Çifçibaşı-Örmeci A., Beşişik F., Çalışkan Y., et al.
Balkan medical journal, vol.40, no.3, pp.182-187, 2023 (SCI-Expanded)
- II. **Mucocutaneous Manifestations and Associated Factors in Patients with Crohn's Disease**
Kayar Y., Dertli R., Konür Ş., Ağin M., Al Kafee A., Baran B., Çiftçibaşı Örmeci A., Akyüz F., Demir K., Beşişik F., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.33, no.11, pp.945-954, 2022 (SCI-Expanded)
- III. **SINGLE CENTER EXPERIENCE OF WILSON DISEASE**
Demir K., Örmeci A. C., Cavus B., Akyuz F., Besisik F., Kaymakoglu S.
HEPATOLOGY, vol.76, 2022 (SCI-Expanded)
- IV. **What is the effect of subepithelial lesions of the esophagus on esophageal motility?**
Örmeci A., Cavus B., Akas R., İstemihan Z., İmanov Z., Senkal V., Nuriyev K., Bayraktar A., Kuelle C. B., Keskin M., et al.
European review for medical and pharmacological sciences, vol.26, no.17, pp.6300-6309, 2022 (SCI-Expanded)
- V. **Is anterior segment OCT superior to slit-lamp biomicroscopic examination for Kayser Flesicher ring in Wilson's disease?**
Örmeci A., Bayraktar S., Isik A. O., Cavus B., Akas R., İstemihan Z., Saridal M. K., Akyuz F., Besisik F., Kaymakoglu S., et al.
European review for medical and pharmacological sciences, vol.26, no.14, pp.5178-5185, 2022 (SCI-Expanded)
- VI. **Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center**
Evirgen S., İliaz R., Akyuz F., Cavus B., Gokturk S., Örmeci A., Soyer O. M., Baran B., Pinarbasi B., Karaca C., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.6, pp.463-469, 2022 (SCI-Expanded)
- VII. **Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?**
Çavuş B., Akyüz F., Örmeci Çifçibaşı A., Özgür İ., Erel C., Yakut A., İmanov Z., Şenkal İ. V., Medetalibeyoğlu A., Köse M.,

et al.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, vol.33, no.3, pp.196-204, 2022 (SCI-Expanded)

- VIII. **Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?**
Cavus B., Akyuz F., Iliaz R., Atasoy A., Akyuz U., Demir K., Besisik F., Kaymakoglu S.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol.36, 2022 (SCI-Expanded)
- IX. **A mysterious cause of recurrent acute liver dysfunction for over a decade**
Dirim A. B., Kalayci T., Guzel Dirim M., Demir S., Cavus B., Cifcibasi Ormeci A., Akyuz F., Kaymakoglu S.
GASTROENTEROLOGY REPORT, vol.10, 2022 (SCI-Expanded)
- X. **Can Interferon Therapy Change the Natural Course of Hepatitis Delta Infection?: a Clinical and Pathological Study**
BAKKALOĞLU O. K., Yildirim O., Cavus B., Evirgen S., Gokturk S., Ormeci A., Soyer O., Akyuz F., Demir K., Kaymakoglu S., et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.66, no.1, 2022 (SCI-Expanded)
- XI. **Prevalence and Association of Restless Leg Syndrome, Depression and Anxiety in Patients With Inflammatory Bowel Disease**
Iliaz R., Ozturk N. B., Kilicarslan A. F., Akas R., Guzey D. Y., Senel E., Akbaba B., Demir K., Kaymakoglu S., Besisik F., et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.116, 2021 (SCI-Expanded)
- XII. **Is belching increasing after bariatric bypass surgery in the long term period?**
Akyüz F., Göksoy B., Telli P., Nizam N., Atasoy A., Çavus B., ÇALIKOĞLU B. F., Demir K., Kaymakoglu S., Beşışık F., et al.
Acta gastro-enterologica Belgica, vol.84, no.4, pp.601-605, 2021 (SCI-Expanded)
- XIII. **Complementary Roles of Cadaveric and Living Donor Liver Transplantation in Acute Liver Failure.**
Özden İ., Yavru H. A., Durmaz Ö., Orhun G., Salmashoğlu A., Güllüoğlu M., Alper A., İbiş C., Serin K. R., Önal Z., et al.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, vol.25, no.10, pp.2516-2523, 2021 (SCI-Expanded)
- XIV. **Etiology of Cirrhosis in Turkey: A National Cohort Study**
YILDIRIM A. E., ÜÇBİLEK E., Oruncu M. B., TURAN İ., DEMİR M., Koksak A., UYANIKOĞLU A., Yilmaz N., AKARSU M., Tozlu M., et al.
JOURNAL OF HEPATOLOGY, vol.75, 2021 (SCI-Expanded)
- XV. **The development of extraintestinal manifestation and related risk factors in Crohn's patients**
Kayar Y., Dertli R., Konur S., Agin M., Baran B., Ormeci A., Akyuz F., Demir K., Besisik F., Kaymakoglu S.
IRISH JOURNAL OF MEDICAL SCIENCE, vol.190, no.2, pp.597-604, 2021 (SCI-Expanded)
- XVI. **The case for simplifying and using absolute targets for viral hepatitis elimination goals**
Razavi H., Blach S., Razavi-Shearer D., Abaalkhail F., Abbas Z., Abdallah A., Abrao Ferreira P., Abu Raddad L. J., Adda D., Agarwal K., et al.
Journal of Viral Hepatitis, vol.28, no.1, pp.12-19, 2021 (SCI-Expanded)
- XVII. **The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists**
Kabacam G., Dayangac M., ÜÇBİLEK E., Ercin C. N., Gunsar F., Akyilchz M., AKARSU M., Demira M., Kaymakoglu S., Karasus Z., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, no.5, pp.348-355, 2020 (SCI-Expanded)
- XVIII. **A micro-elimination approach to addressing hepatitis C in Turkey**
İDİLMAN R., Razavi H., Robbins-Scott S., AKARCA U. S., ÖRMECİ N., Kaymakoglu S., AYGEN B., Tozun N., Guner R., Bodur H., et al.
BMC HEALTH SERVICES RESEARCH, vol.20, no.1, 2020 (SCI-Expanded)
- XIX. **The effect of liver test abnormalities on the prognosis of COVID-19.**
Medetalibeyoglu A., Catma Y., Senkal N., Ormeci A., Cavus B., Kose M., Bayramlar O. F., Yildiz G., Akyuz F., Kaymakoglu S., et al.

Annals of hepatology, vol.19, no.6, pp.614-621, 2020 (SCI-Expanded)

- XX. **Changing epidemiology of chronic hepatitis C: patients are older and at a more advanced stage at the time of diagnosis**
Iliaz R., Yuce T., Torun S., Cavus B., Gulluoglu M., Bozaci M., Karaca C., Akyuz F., Demir K., Besisik F., et al.
European journal of gastroenterology & hepatology, vol.31, no.10, pp.1247-1249, 2019 (SCI-Expanded)
- XXI. **Risk factors associated with progression to intestinal complications of Crohn disease**
Kayar Y., Baran B., Ormeci A., Akyuz F., Demir K., Besisik F., Kaymakoglu S.
CHINESE MEDICAL JOURNAL, vol.132, no.20, pp.2423-2429, 2019 (SCI-Expanded)
- XXII. **THE ASSESSMENT OF RENAL TRANSPLANT PATIENTS REGARDING MICRO-ELIMINATION OF CHRONIC VIRAL HEPATITISES IN TURKEY: AN ANALYSIS OF 2410 PATIENTS**
Turkmen A., Bakir E. A., Bolukbas C., Sinangil A., Kocak E., Uyar M., Yildiz H., Gunay E., Kaya S., Organ K., et al.
TRANSPLANT INTERNATIONAL, vol.32, pp.194, 2019 (SCI-Expanded)
- XXIII. **The Clinical Significance of JAK2V617F Mutation for Philadelphia-Negative Chronic Myeloproliferative Neoplasms in Patients with Splanchnic Vein Thrombosis**
Hindilerden F., Hindilerden I. Y., Pinarbasi B., HANÇER V. S., Kaymakoglu S., Kucukkaya R. D., Nalcaci M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, 2019 (SCI-Expanded)
- XXIV. **Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?**
Akyuz F., Cavus B., Iliaz R., Soyer O. M., Ormeci A., Evirgen S., Onder S., Koksalan K., Keskin M., Karaca C., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.31, no.7, pp.777-780, 2019 (SCI-Expanded)
- XXV. **Cryptogenic liver cirrhosis and hepatitis E virus (HEV): Are they related?**
Akyuz F., Cavus B., Pinarbasi B., Bozaci M., Baran B., Akyuz U., Uyanikoglu A., Demir K., Besisik F., Ozdil S., et al.
Annals of Hepatology, vol.18, no.4, pp.585-589, 2019 (SCI-Expanded)
- XXVI. **Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort**
İDİLMAN R., DEMİR M., ALADAĞ M., Erol C., Cavus B., Iliaz R., Koklu H., Cakaloglu Y., Sahin M., ERSÖZ G., et al.
JOURNAL OF VIRAL HEPATITIS, vol.26, no.6, pp.666-674, 2019 (SCI-Expanded)
- XXVII. **Evaluation of drug resistance mutations in patients with chronic hepatitis B**
Alaçam S., Karabulut N., Yolcu A., Onel M., Atasoy A., Kaymakoglu S., Agacfidan A.
FOLIA MICROBIOLOGICA, vol.64, no.2, pp.237-243, 2019 (SCI-Expanded)
- XXVIII. **Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?**
İLİAZ R., AKYÜZ F., Yeğen G., ÖRMECİ A., GÖKTÜRK S., AKYÜZ Ü., BARAN B., MUTLUAY Ö., EVİRGEN S., KARACA Ç., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.4, pp.384-391, 2018 (SCI-Expanded)
- XXIX. **Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study**
Razavi-Shearer D., Gamkrelidze I., Nguyen M. H., Chen D., Van Damme P., Abbas Z., Abdulla M., Abou Rached A., Adda D., Aho I., et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY, vol.3, no.6, pp.383-403, 2018 (SCI-Expanded)
- XXX. **Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report**
AYGEN B., DEMİR A. M., GÜMÜŞ M., Karabay O., Kaymakoglu S., KÖKSAL A. Ş., Koksali I., ÖRMECİ N., Tabak F.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.3, pp.259-269, 2018 (SCI-Expanded)
- XXXI. **Mutations in Core Gene Region of Hepatitis B Virus in Patients with Chronic Hepatitis B.**
Ciftci S., Keskin F., Abaci N., Akyuz F., Cakiris A., Badur S., Kaymakoglu S., Ustek D.
Clinical laboratory, vol.64, pp.303-310, 2018 (SCI-Expanded)
- XXXII. **Predicting mortality in patients with spontaneous bacterial peritonitis using routine inflammatory and biochemical markers**
Iliaz R., Ozpolat T., Baran B., Demir K., Kaymakoglu S., Besisik F., Akyuz F.
European Journal of Gastroenterology and Hepatology, vol.30, no.7, pp.786-791, 2018 (SCI-Expanded)
- XXXIII. **Turkey 2017 Clinical Practice Guidelines on recommendations for screening diagnosing and managing hepatitis C virus**

Idilman R., Baykam N., KAYMAKOĞLU S., Tabak F., Bahcecioglu H. I., Bektas A., Bulut C., Gunsar F., Inan D., Karaosmanoglu H. K., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)

XXXIV. **Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines**

Tabak F., Yurdaydin C., KAYMAKOĞLU S., Tabak F., AKARSU M., Akinci E. G., Akkiz H., Alkim C., Cekin A. H., Cuvalci N. O., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)

XXXV. **Recommendation for treatment of hepatitis C virus infection**

KAYMAKOĞLU S., Koksali I., KAYMAKOĞLU S., Tabak F., Akarca U. S., Akbulut A., AKYÜZ F., Bodur H., ÇAĞATAY A. A., Dincer D., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)

XXXVI. **Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines**

Yurdaydin C., Tabak F., KAYMAKOĞLU S., Tabak F., AKARSU M., Akinci E. G., Akkiz H., Alkim C., Cekin A. H., Cuvalci N. O., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.28, 2017 (SCI-Expanded)

XXXVII. **Role of biochemistry and cytological analysis of cyst fluid for the differential diagnosis of pancreatic cysts A retrospective cohort study**

Soyer O. M., Baran B., Ormeci A., Sahin D., Gokturk S., Evirgen S., Basar R., Firat P., Akyuz F., Demir K., et al.

MEDICINE, vol.96, no.1, 2017 (SCI-Expanded)

XXXVIII. **Belching in irritable bowel syndrome: An impedance study**

Obekli T., Akyuz F., Akyuz U., Arici S., Iliaz R., Gokturk S., Evirgen S., Cavus B., Karaca C., Demir K., et al.

Journal of Neurogastroenterology and Motility, vol.23, no.3, pp.409-414, 2017 (SCI-Expanded)

XXXIX. **Analysis of hepatitis C virus NS5A region in patients with cirrhosis using an ultra-deep pyrosequencing method**

Keskin F., Ciftci S., Akyuz F., Abaci N., Cakiris A., Akyuz U., Demir K., Besisik F., Ustek D., Kaymakoglu S.

Clinical Laboratory, vol.63, no.9, pp.1439-1445, 2017 (SCI-Expanded)

XL. **Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma**

Iliaz R., Akyuz U., Tekin D., Serilmez M., Evirgen S., Cavus B., Soyduinc H., Duranyildiz D., Karaca C., Demir K., et al.

Arab Journal of Gastroenterology, vol.17, no.4, pp.164-167, 2016 (SCI-Expanded)

XLI. **Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels**

Ormeci A., Aydin Y., Sumnu A., Baran B., Soyer O. M., Pinarbasi B., Gokturk S., Gulluoglu M., Onel D., Badur S., et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, vol.52, pp.68-73, 2016 (SCI-Expanded)

XLII. **Retention during capsule endoscopy: Is it a real problem in routine practice?**

Ormeci A., Akyuz F., Baran B., Gokturk S., Ormeci T., Pinarbasi B., Soyer O. M., Evirgen S., Akyuz U., Karaca C., et al.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol.44, no.4, pp.968-975, 2016 (SCI-Expanded)

XLIII. **Does gastroesophageal reflux increase chronic obstructive pulmonary disease exacerbations?**

Iliaz S., Iliaz R., Onur S. T., Arici S., Akyuz U., Karaca C., Demir K., Besisik F., Kaymakoglu S., Akyuz F.

Respiratory Medicine, vol.115, pp.20-25, 2016 (SCI-Expanded)

XLIV. **Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?**

ORMECI A., Emrence Z., BARAN B., SOYER O., GOKTURK S., EVIRGEN S., AKYUZ F., KARACA C., BESISIK F., KAYMAKOGLU S., et al.

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.20, no.9, pp.1795-1797, 2016 (SCI-Expanded)

XLV. **Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study**

Soyer O. M., Baran B., Ormeci A., Gokturk S., Aydin E., Onel D., Gulluoglu M., Karaca C., Akyuz F., Demir K., et al.

POSTGRADUATE MEDICINE, vol.128, no.4, pp.432-438, 2016 (SCI-Expanded)

- XLVI. **Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole**
Ormeçi A., Emrence Z., Baran B., Gokturk S., Soyer O. M., Evirgen S., Akyuz F., Karaca C., Besisik F., Kaymakoglu S., et al.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.20, no.5, pp.879-885, 2016 (SCI-Expanded)
- XLVII. **Steroid-refractory inflammatory bowel disease is a risk factor for CMV infection**
Ormeçi A., Akyuz F., BARAN B., SOYER O., GÖKTÜRK S., ONEL M., ONEL D., AGACFIDAN A., DEMIRCI M., Yegen G., et al.
European Review for Medical and Pharmacological Sciences, vol.20, no.5, pp.858-865, 2016 (SCI-Expanded)
- XLVIII. **Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study**
Tozun N., Ozdogan O., Cakaloglu Y., Idilman R., Karasu Z., Akarca U., Kaymakoglu S., Ergonul O.
CLINICAL MICROBIOLOGY AND INFECTION, vol.21, no.11, pp.1020-1026, 2015 (SCI-Expanded)
- XLIX. **Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus**
Baran B., Soyer O. M., Ormeçi A., Gokturk S., Evirgen S., Akyuz F., Karaca C., Demir K., Besisik F., Onel D., et al.
LIVER INTERNATIONAL, vol.35, no.10, pp.2265-2274, 2015 (SCI-Expanded)
- L. **Small bowel mucosal damage in familial Mediterranean fever: results of capsule endoscopy screening**
Demir A., Akyuz F., Gokturk S., Evirgen S., Akyuz U., Ormeçi A., Soyer O., Karaca C., Demir K., Gundogdu G., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol.49, no.12, pp.1414-1418, 2014 (SCI-Expanded)
- LI. **Effects of Polymorphisms in Interferon lambda 3 (Interleukin 28B) on Sustained Virologic Response to Therapy in Patients With Chronic Hepatitis D Virus Infection**
Yilmaz E., Baran B., Soyer O. M., Onel M., Onel D., Ormeçi A., Gokturk S., Evirgen S., Akyuz F., Demir K., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, vol.12, no.10, pp.1753-1758, 2014 (SCI-Expanded)
- LII. **Infliximab in inflammatory bowel disease: attention to adverse events**
Uyanikoglu A., Ermis F., Akyuz F., Pinarbasi B., Baran B., Aydogan T., Demir K., Besisik F., Kaymakoglu S.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol.18, no.16, pp.2337-2342, 2014 (SCI-Expanded)
- LIII. **Acute hepatitis B due to immune-escape mutations in a naturally immune patient**
Kaymakoglu S., Baran B., Onel D., Badur S., Atamer T., Akyuz F.
ACTA GASTRO-ENTEROLOGICA BELGICA, no.2, pp.262-265, 2014 (SCI-Expanded)
- LIV. **Strategies to manage hepatitis C virus (HCV) disease burden**
Wedemeyer H., Duberg A. S., Buti M., Rosenberg W. M., Frankova S., Esmat G., Ormeçi N., Van Vlierberghe H., Gschwantler M., Akarca U., et al.
JOURNAL OF VIRAL HEPATITIS, vol.21, pp.60-89, 2014 (SCI-Expanded)
- LV. **The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm**
Razavi H., Waked I., Sarrazin C., Myers R. P., Idilman R., Calinas F., Vogel W., Mendes Correa M. C., Hezode C., Lazaro P., et al.
JOURNAL OF VIRAL HEPATITIS, vol.21, pp.34-59, 2014 (SCI-Expanded)
- LVI. **Historical epidemiology of hepatitis C virus (HCV) in selected countries**
Bruggmann P., Berg T., Ovrehus A. L. H., Moreno C., Brandao Mello C. E., Roudot-Thoraval F., Marinho R. T., Sherman M., Ryder S. D., Sperl J., et al.
JOURNAL OF VIRAL HEPATITIS, vol.21, pp.5-33, 2014 (SCI-Expanded)
- LVII. **Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method**
Ciftci S., Keskin F., Cakiris A., Akyuz F., Pinarbasi B., Abaci N., Dincer E., Badur S., Kaymakoglu S., Ustek D.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol.79, no.1, pp.25-30, 2014 (SCI-Expanded)

- LVIII. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C**
Baran B., Gulluoglu M., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Yesil S., Akyuz F., Karaca C., Demir K., et al.
JOURNAL OF VIRAL HEPATITIS, vol.21, no.2, pp.111-120, 2014 (SCI-Expanded)
- LIX. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B**
KESKİN O., Ormeci A., Baran B., Kabacam G., Tuzun A., Karatayli E., Akyuz F., Karatayli S., BOZDAYI A. M., Onel D., et al.
ANTIVIRAL THERAPY, vol.19, no.6, pp.543-550, 2014 (SCI-Expanded)
- LX. Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients**
Mese S., Arikan M., Cakiris A., Abaci N., Gumus E., Kursun O., Onel D., Ustek D., Kaymakoglu S., Badur S., et al.
JOURNAL OF GENERAL VIROLOGY, vol.94, pp.2729-2738, 2013 (SCI-Expanded)
- LXI. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C**
Uyanikoglu A., Akyuz F., Baran B., Simsek B. P., Ermis F., Demir K., Gulluoglu M., Badur S., Kaymakoglu S.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.37, no.5, pp.485-490, 2013 (SCI-Expanded)
- LXII. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients**
Avsar E., TIFTIKCI A., Poturoglu S., Erzin Y., KOCAKAYA O., DİNÇER D., Yildirim B., Guliter S., Turkay C., Yilmaz U., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.24, no.4, pp.316-321, 2013 (SCI-Expanded)
- LXIII. Rosai-Dorfman disease with diffuse gastrointestinal involvement**
Baran B., Karaca C., Soyer O. M., Yonal I., Isiklar A. D., Cakmak R., Nalcaci M., Dogan O., Kaymakoglu S.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, vol.25, no.7, pp.869-874, 2013 (SCI-Expanded)
- LXIV. Durability of sustained virologic response in chronic hepatitis C**
UYANIKOĞLU A., Kaymakoglu S., Danalioglu A., Akyuz F., Ermis F., Pinarbasi B., Demir K., Besisik F., Cakaloglu Y.
Gut and Liver, vol.7, no.4, pp.458-461, 2013 (SCI-Expanded)
- LXV. Effect of Genotypic Differences in CYP2C19 and on Cure Rates for Helicobacter pylori Infection by Triple Therapy With Different Proton Pump Inhibitors**
Demir K., ORMECI A., Emrence Z., Gokturk S., Baran B., SOYER O. M., Akyuz F., Karaca C., BESISIK F., Kaymakoglu S., et al.
GASTROENTEROLOGY, vol.144, no.5, 2013 (SCI-Expanded)
- LXVI. Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naive Patients with Chronic Hepatitis B**
Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Bozbey H. U., Akyuz F., Karaca C., Demir K., Besisik F., et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.57, no.4, pp.1790-1796, 2013 (SCI-Expanded)
- LXVII. Association of the MEFV Gene Variations With Inflammatory Bowel Disease in Turkey**
Akyuz F., Besisik F., Ustek D., Ekmekci C., Uyar A., Pinarbasi B., Demir K., Ozdil S., Kaymakoglu S., Boztas G., et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.47, no.3, 2013 (SCI-Expanded)
- LXVIII. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response**
Karaca C., Soyer O. M., Baran B., Ormeci A., Gokturk S., Aydin E., Evirgen S., Akyuz F., Demir K., Besisik F., et al.
ANTIVIRAL THERAPY, vol.18, no.4, pp.561-566, 2013 (SCI-Expanded)
- LXIX. Measurement of the coronary flow velocity reserve in patients with non-alcoholic fatty liver disease**
Pinarbasi B., Demir K., Oflaz H., Ahishali E., Akyuz F., Elitok A., Cimen A. O., Golcuk E., Gulluoglu M., Issever H., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.23, no.6, pp.720-726, 2012 (SCI-Expanded)
- LXX. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis**
Yonal I., Pinarbasi B., Hindilerden F., Hancer V. S., Nalcaci M., Kaymakoglu S., Diz-Kucukkaya R.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, vol.34, no.3, pp.388-396, 2012 (SCI-Expanded)

- LXXI. **Etiological factors of duodenal and gastric ulcers**
Uyanikoglu A, Danalioglu A, Akyuz F, Ermis F, Gulluoglu M, Kapran Y, Demir K, Ozdil S, Besisik F, Boztas G., et al.
Turkish Journal of Gastroenterology, vol.23, no.2, pp.99-103, 2012 (SCI-Expanded)
- LXXII. **Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV1 origins**
Le Gal F, Badur S, Al Hawajri N, Akyuz F, Kaymakoglu S, Brichler S, Zoulim F, Gordien E, Gault E, Deny P.
ARCHIVES OF VIROLOGY, vol.157, no.4, pp.647-659, 2012 (SCI-Expanded)
- LXXIII. **Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?**
Yonal O., Hatemi G., Kaymakoglu S.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.23, pp.21-24, 2012 (SCI-Expanded)
- LXXIV. **Second-Line Levofloxacin-Based Triple Therapy's Efficiency for Helicobacter pylori Eradication in Patients With Peptic Ulcer**
Ermis F, Akyuz F, Uyanikoglu A, Kurt R, Pinarbasi B, Nazik H, Kaymakoglu S, Mungan Z.
SOUTHERN MEDICAL JOURNAL, vol.104, no.8, pp.579-583, 2011 (SCI-Expanded)
- LXXV. **Postprandial platelet-poor plasma 5-hydroxytryptamine concentrations during diarrhea and constipation periods of alternatingtype irritable bowel syndrome patients**
Sen F, Pinarbasi B, Issever H, Akyuz F, Mungan Z, Kaymakoglu S.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.22, no.3, pp.270-278, 2011 (SCI-Expanded)
- LXXVI. **Anticoagulant therapy and Budd-Chiari syndrome: Is it successful?**
Akyuz F, Cakaloglu Y, Pinarbasi B, Demir K, Akyuz U, Ozdil S, Besisik F, Boztas G, Mungan Z, Kaymakoglu S.
Hepato-Gastroenterology, vol.58, pp.900-903, 2011 (SCI-Expanded)
- LXXVII. **Effect of proton pump inhibitor (PPI) treatment in obstructive sleep apnea syndrome: An esophageal impedance-pHmetry study**
Ermis F, Akyuz F, Arici S, Uyanikoglu A, Yakar F, Pinarbasi B, Demir K, Ozdil S, Besisik F, Kaymakoglu S., et al.
Hepato-Gastroenterology, vol.58, pp.1566-1573, 2011 (SCI-Expanded)
- LXXVIII. **Decreased prohepcidin levels in patients with HBV-related liver disease: relation with ferritin levels.**
Yonal O, Akyuz F, Demir K, Ciftci S, Keskin F, Pinarbasi B, Uyanikoglu A, Issever H, Ozdil S, Boztas G., et al.
Digestive diseases and sciences, vol.55, no.12, pp.3548-51, 2010 (SCI-Expanded)
- LXXIX. **Is portal hypertensive enteropathy an important additional cause of blood loss in portal hypertensive patients?**
Akyuz F, Pinarbasi B, Ermis F, Uyanikoglu A, Demir K, Ozdil S, Besisik F, Kaymakoglu S, Boztas G, Mungan Z.
Scandinavian Journal of Gastroenterology, vol.45, no.12, pp.1497-1502, 2010 (SCI-Expanded)
- LXXX. **How should we follow the Crohn's disease patients in remission?**
Yonal O, Kaymakoglu S.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.21, no.1, pp.97-99, 2010 (SCI-Expanded)
- LXXXI. **Electron microscopic findings in non-alcoholic fatty liver disease: Is there a difference between hepatosteatosis and steatohepatitis?**
Ahishali E, Demir K, Ahishali B, Akyuz F, Pinarbasi B, Poturoglu S, Ibrisim D, Gulluoglu M, Ozdil S, Besisik F, et al.
Journal of Gastroenterology and Hepatology (Australia), vol.25, no.3, pp.619-626, 2010 (SCI-Expanded)
- LXXXII. **The quality of life in hemodialysis patients with chronic hepatitis C virus infection**
Akyuz F, Besisik F, Pinarbasi B, Demir K, Kaymakoglu S, Cakaloglu Y, Sever M. S., Okten A.
Turkish Journal of Gastroenterology, vol.20, no.4, pp.243-246, 2009 (SCI-Expanded)
- LXXXIII. **A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients**
Idilman R, Kaymakoglu S, Onder F. O., Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y., et al.
JOURNAL OF VIRAL HEPATITIS, vol.16, no.4, pp.279-285, 2009 (SCI-Expanded)
- LXXXIV. **Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy**
Shouval D, Lai C, Chang T, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J., et al.

JOURNAL OF HEPATOLOGY, vol.50, no.2, pp.289-295, 2009 (SCI-Expanded)

- LXXXV. **Prevalence and virological features of occult hepatitis B virus infection in female sex workers who work uncontrolled in Turkey.**
Pinarbasi B., Onel D., Cosan F., Akyuz F., Dirlik N., Cakaloglu Y., Badur S., Besisik F., Demir K., Okten A., et al.
Liver international : official journal of the International Association for the Study of the Liver, vol.29, no.2, pp.227-30, 2009 (SCI-Expanded)
- LXXXVI. **Are acquired hepatocerebral degeneration and hepatic myelopathy reversible?**
Pinarbasi B., Kalymakoglu S., Matur Z., Akyuz F., Demir K., Besisik F., Ozdil S., Boztas G., Cakaloglu Y., Mitngan Z., et al.
Journal of clinical gastroenterology, vol.43, no.2, pp.176-81, 2009 (SCI-Expanded)
- LXXXVII. **A new agent for tumour necrosis factor-alpha inhibition: In vitro effects of dipyridamole in Crohn's disease**
Poturoglu S., Kaymakoglu S., Polat N. G., Ibrism D., Ahishali E., Akyuz F., Badur S., Demir K., Mungan Z.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, vol.69, no.6, pp.696-702, 2009 (SCI-Expanded)
- LXXXVIII. **Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a**
Marcellin P., Bonino F., Lau G. K., Farci P., Yurdaydin C., Piratvisuth T., Jin R., Gurel S., Lu Z., Wu J., et al.
Gastroenterology, vol.136, no.7, 2009 (SCI-Expanded)
- LXXXIX. **Intestinal metaplasia in portal hypertensive gastropathy: A frequent pathology**
Ibrism D., Cevikbas U., Akyuz F., Poturoglu S., Ahishali E., Gulluoglu M., Demir K., Besiski F., Boztas G., Ozdil S., et al.
European Journal of Gastroenterology and Hepatology, vol.20, no.9, pp.874-880, 2008 (SCI-Expanded)
- XC. **Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus**
Okan G., Yaylaci S., Peker O., Kaymakoglu S., Saruc M.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.14, no.29, pp.4697-4700, 2008 (SCI-Expanded)
- XCII. **Prevalence and clinical significance of SEN-H virus in chronic hepatitis B, C and delta infections in Turkey**
Cakaloglu Y., Akyuz F., Bozaci M., Ibrism D., Pinarbasi B., Demir K., Kaymakoglu S., Besisik F., Badur S., Oekten A.
Turkish Journal of Gastroenterology, vol.19, no.2, pp.104-108, 2008 (SCI-Expanded)
- XCIII. **Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks**
Sherman M., Yurdaydin C., Simsek H., Silva M., Liaw Y., Rustgi V. K., Sette H., Tsai N., Tenney D. J., Vaughan J., et al.
Hepatology, vol.48, no.1, pp.99-108, 2008 (SCI-Expanded)
- XCIV. **MEFV gene mutations and inflammatory bowel disease: Is there any effect?**
AKYÜZ F., Besisik F., Pinarbasi B., DEMİR K., KAYMAKOĞLU S., Ozdil S., Boztas G., Mungan Z. A., GÜL A.
GASTROENTEROLOGY, vol.134, no.4, 2008 (SCI-Expanded)
- XCV. **Peptic ulcer disease: What did change in Turkey?**
Yazici A., AKYÜZ F., İŞSEVER H., Pinarbasi B., DEMİR K., Ozdil S., BEŞİŞİK S. F., Boztas G., Mungan Z. A., KAYMAKOĞLU S.
GASTROENTEROLOGY, vol.134, no.4, 2008 (SCI-Expanded)
- XCVI. **A rare cause of hemosuccus pancreaticus: Primary splenic artery aneurysm ruptured into pancreatic serous cystadenoma**
Pinarbasi B., Poturoglu S., Yanar H., Gueven K., Akyuz F., Dizdaroglu F., Guellueoglu M., Taviloglu K., Kaymakoglu S., Mungan Z.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.19, no.1, pp.57-63, 2008 (SCI-Expanded)
- XCVII. **Somatostatin and propranolol to treat small-for-size syndrome that occurred despite splenic artery ligation**
Oezden I., Kara M., Pinarbasi B., Salmaslioglu A., Yavru A., Kaymakoglu S., Emre A., Bilge O., Alper A.
EXPERIMENTAL AND CLINICAL TRANSPLANTATION, vol.5, no.2, pp.686-689, 2007 (SCI-Expanded)
- XCVIII. **HFE gene mutation, chronic liver disease, and iron overload in Turkey**

- YOENAL O., Hatirnaz O., AKYUEZ F., Oezbek U., Demir K., Kaymakoglu S., OEKTEN A., MUNGAN Z.
DIGESTIVE DISEASES AND SCIENCES, vol.52, no.11, pp.3298-3302, 2007 (SCI-Expanded)
- XCVIII. **The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease**
Akyuez F., Demir K., Oezdil S., Aksoy N., Poturoglu S., Ibrism D., Kaymakoglu S., Besisik F., Boztas G., Cakaloglu Y., et al.
Digestive Diseases and Sciences, vol.52, no.9, pp.2359-2367, 2007 (SCI-Expanded)
- XCIX. **A case of Aeromonas hydrophila enteritis in the course of ulcerative colitis**
Ahishali E., Pinarbasi B., Akyuz F., Ibrism D., Kaymakoglu S., Mungan Z.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, vol.18, no.5, pp.430-431, 2007 (SCI-Expanded)
- C. **Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B**
Kaymakoglu S., Oguz D., Gur G., Gurel S., Tankurt E., Ersoz G., Ozenirler S., Kalayci C., Poturoglu S., Cakaloglu Y., et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol.51, no.8, pp.3020-3022, 2007 (SCI-Expanded)
- CI. **Eosinophilic esophagitis: Case report**
Mungan Z., Pinarbasi B., Kaymakoglu S.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.18, no.2, pp.100-102, 2007 (SCI-Expanded)
- CII. **Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B**
Kaymakoglu S., Danalioglu A., Demir K., Karaca C., Akyuz F., Onel D., Badur S., Cevikbas U., Besisik F., Cakaloglu Y., et al.
Digestive Diseases and Sciences, vol.52, no.3, pp.727-731, 2007 (SCI-Expanded)
- CIII. **Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy**
Akyuz F., Kaymakoglu S., Demir K., Aksoy N., Karaca C., Danalioglu A., Onel D., Badur S., Besisik F., Cakaloglu Y., et al.
Acta Gastro-Enterologica Belgica, vol.70, no.1, pp.20-24, 2007 (SCI-Expanded)
- CIV. **Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels**
Akyuz F., Polat N., Kaymakoglu S., Aksoy N., Demir K., Besisik F., Badur S., Cakaloglu Y., Okten A.
World Journal of Gastroenterology, vol.11, no.45, pp.7188-7191, 2005 (SCI-Expanded)
- CV. **Merkel-cell carcinoma arising after liver transplantation: A case report**
Esen B., PINARBASI B., Buyukbabani N., Baykal C., Cizmeci O., Demir K., ACARLI K. S., Kaymakoglu S.
TRANSPLANTATION PROCEEDINGS, vol.37, no.10, pp.4413-4415, 2005 (SCI-Expanded)
- CVI. **Psychiatric morbidity and quality of life in chronic hepatitis patients**
Ozkan M., Corapcioglu A., Balcioglu I., Ertekin E., Koroglu G., Ozdemir S., Karayun D., Ozen B., Kocaman N., KAYMAKOĞLU S., et al.
JOURNAL OF PSYCHOSOMATIC RESEARCH, vol.59, no.1, pp.42, 2005 (SCI-Expanded)
- CVII. **Crohn disease activity evaluated by Doppler ultrasonography of the superior mesenteric artery and the affected small-bowel segments**
YEKELER E., DANALIOGLU A., MOVASSEGI B., YILMAZ S., KARACA C., KAYMAKOGLU S., Acunas B.
JOURNAL OF ULTRASOUND IN MEDICINE, vol.24, no.1, pp.59-65, 2005 (SCI-Expanded)
- CVIII. **Interferon-alpha(2b) induction treatment with or without ribavirin in chronic hepatitis C - A multicenter, randomized, controlled trial**
Senturk H., Ersoz G., Ozaras R., Kaymakoglu S., Bozkaya H., Akdogan M., Mert A., Bozdayi M., Tabak F., Yenice N., et al.
DIGESTIVE DISEASES AND SCIENCES, vol.48, no.6, pp.1124-1129, 2003 (SCI-Expanded)
- CIX. **The prevalence of manifest and latent celiac disease in type 1 diabetes mellitus**
GÜVENÇ S., KAYMAKOĞLU S., GÜREL N., KARŞIDAĞ K., DEMİR K., DİNÇER D., ÇINAR Ç., SALMAN S., YILMAZ T., BEŞİŞİK S. F., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, no.13, pp.103-107, 2002 (SCI-Expanded)
- CX. **Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome**

Diz-Kucukkaya R., Demir K., Yenerel M. N., Nalcaci M., Kaymakoglu S., Inanc M.
HAEMATOLOGIA, vol.32, no.1, pp.73-77, 2002 (SCI-Expanded)

CXI. Miconazole induced acute hepatitis and sexual intercourse!

Beşişik F., Dinçer D., DEMİR K., KAYMAKOĞLU S., Çakalöglü Y., Çevikbaş U., ÖKTEN A.
Turkish Journal of Gastroenterology, vol.12, no.1, pp.59-63, 2001 (SCI-Expanded)

Articles Published in Other Journals

- I. **TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.**
YILMAZ Y., ZEYBEL M., ADALI G., COŞAR A. M., SERTESEN E., GÖKCAN H., BAHÇECİOĞLU İ. H., Şahin M., TULUNAY KAYA C., ERGÜN İ., et al.
Hepatology forum, vol.4, no.Suppl 1, pp.1-32, 2023 (ESCI)
- II. **Two Cases of Malignant Transformation in Crohn's Disease with Perianal Involvement**
DAĞCI G., VARELCİ S., BÜYÜK M., ÇAVUŞ B., ÇİFCİBAŞI ÖRMECİ A., AKYÜZ F., KAYMAKOĞLU S.
Kare Publishing, vol.2, 2023 (Peer-Reviewed Journal)
- III. **Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score's prediction factor for survival?**
Evirgen S., ÇAVUŞ B., Gokturk S., Iliaz R., ÖZKAN Z. G., Baran B., ÇİFCİBAŞI ÖRMECİ A., Soyer O. M., Karaca C., DEMİR K., et al.
Hepatology Forum, vol.4, no.3, pp.103-107, 2023 (Scopus)
- IV. **Different Faces of Eosinophilic Infiltration of Gastrointestinal System**
İSTEMİHAN Z., ÇAVUŞ B., BERKER N., Nuriyev K., Şenkal V., İmanov Z., Rüstemezade A., GENÇ S., POYANLI A., ÇİFCİBAŞI ÖRMECİ A., et al.
Journal of Enterocolitis, vol.1, no.3, pp.68-71, 2022 (Peer-Reviewed Journal)
- V. **Cell-free methylation of RASSF1 and CDKN2AIP genes in the diagnosis of hepatocellular carcinoma associated with hepatitis B virus cirrhosis**
Telli P., Ozturk N. B., Hakan M. T., Cavus B., Ormeci A. C., Yakut A., Senkal V., İmanov Z., Poyanli A., Isik E. G., et al.
HEPATOLOGY FORUM, vol.3, no.3, pp.77-81, 2022 (ESCI)
- VI. **Eliminating Viral Hepatitis in Turkey: Achievements and Challenges**
AKARCA U. S., BAYKAM N., GÜNER H. R., GÜNŞAR F., İDİLMAN R., Kaymakoglu S., KÖKSAL I., TABAK Ö. F., YAMAZHAN T.
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, no.2, pp.47-54, 2022 (ESCI)
- VII. **A Case of Budd-Chiari Syndrome Associated With Antiphospholipid Syndrome Treated Successfully by Transjugular Intrahepatic Portosystemic Shunt**
Torun E. S., Erciyestepe M., Yalcinkaya Y., Gul A., Inanc M., Ocal L., Kaymakoglu S., PEYNİRCİOĞLU B., Artim-Esen B.
CLINICAL MEDICINE INSIGHTS-CASE REPORTS, vol.15, 2022 (ESCI)
- VIII. **Are Hepatobiliary Manifestations Related to the Site of Involvement in Inflammatory Bowel Disease?**
İstemihan Z., Çıfcıbaşı Örmeci A., Çavuş B., Şenkal İ. V., İmanov Z., Nuriyev K., Akyüz F., Demir K., Beşişik S. F., Kaymakoglu S.
Journal of Enterocolitis, vol.1, pp.12-16, 2022 (Peer-Reviewed Journal)
- IX. **Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data.**
Akyüz F., Çavuş B., Nizam N., Göktürk S., Baran B., Yazıcı H., Evirgen S., Akyüz Ü., Öbekli T., Karaca Ç., et al.
Clinical and experimental hepatology, vol.8, no.1, pp.7-13, 2022 (Peer-Reviewed Journal)
- X. **EVALUATION OF HELICOBACTER PYLORI FREQUENCY AND GASTRIC ANTRUM PATHOLOGY FINDINGS IN PATIENTS WITH PORTAL HYPERTENSION**
Cavus B., Ormeci A., Evirgen S., Iliaz R., Atasoy A., Yegen G., Demir K., Besisik S. F., Kaymakoglu S., Akyuz F.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGISI, vol.85, no.2, pp.211-215, 2022 (ESCI)

- XI. **ATA Index: A novel score for predicting fibrosis stage in chronic viral hepatitis**
Tugsal H. Y., Yuksel S., Kabacam G., Evirgen S., Akan K., Akyuz F., Gulluoglu M., Erden E., Bozdayi A. M., Cinar K., et al.
Hepatology Forum, vol.2, no.1, pp.12-19, 2021 (Scopus)
- XII. **Hepatocellular Carcinoma Metastasis to the Foot**
Seyithanoglu D., Cavus B., Ciftibasi Ormeci A., Buyukbabani N., Poyanli A., Kaymakoglu S.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, vol.36, no.2, pp.234-235, 2021 (ESCI)
- XIII. **Steroid-induced reconstitution of the biliary tree ravaged by IgG4-related disease**
Ozden I., Poyanli A., Sanli Y., Kaymakoglu S.
CLINICAL CASE REPORTS, vol.8, no.12, pp.3553-3554, 2020 (ESCI)
- XIV. **Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma**
Serilmez M., Akyuz F., Ormeci Ciftibasi A., Karabulut S., Kaymakoglu S., Yasasever V., Duranyildiz D.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, vol.33, no.1, pp.18-27, 2018 (ESCI)
- XV. **Current state and clinical outcome in Turkish patients with hepatocellular carcinoma**
Ekinci O., Baran B., Ormeci A., Soyer O. M., Gokturk S., Evirgen S., Poyanli A., Gulluoglu M., Akyuz F., Karaca C., et al.
WORLD JOURNAL OF HEPATOLOGY, vol.10, no.1, pp.51-61, 2018 (ESCI)
- XVI. **Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study**
Blach S., Zeuzem S., Manns M., Altraif I., Duberg A., Muljono D. H., Waked I., Alavian S. M., Lee M., Negro F., et al.
The Lancet Gastroenterology and Hepatology, vol.2, no.3, pp.161-176, 2017 (Scopus)
- XVII. **What is the impact of capsule endoscopy in the long term period?**
Ormeci A., Akyuz F., Baran B., Gokturk S., Ormeci T., Pinarbasi B., Soyer O. M., Evirgen S., Akyuz U., Karaca C., et al.
WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY, vol.8, no.7, pp.344-348, 2016 (ESCI)
- XVIII. **Viral hepatitis screening guideline before biological drug use in rheumatic patients**
KARADAĞ Ö., Kasifoglu T., Ozer B., Kaymakoglu S., KUS Y., Inanc M., KESER G., KIRAZ S.
EUROPEAN JOURNAL OF RHEUMATOLOGY, vol.3, no.1, pp.25-28, 2016 (ESCI)
- XIX. **ROLE OF THE TACROLIMUS IN POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME**
Orhan E. K., Alpsan H., Bebek N., Pinarbasi B., Kaymakoglu S., Ozden I., Coban O.
NOBEL MEDICUS, vol.11, no.3, pp.80-83, 2015 (ESCI)
- XX. **Role of the tacrolimus in posterior reversible encephalopathy syndrome Posterior Geri Dönüşümlü Ensefalopati Sendromunda Tacrolimus'un Rolü**
Orhan E., ALPSAN H., BEBEK N., PINARBAŞI B., KAYMAKOĞLU S., ÖZDEN İ., ÇOBAN O.
Nobel Medicus, vol.11, no.3, pp.80-83, 2015 (Scopus)
- XXI. **In Situ Adenocarcinoma of the Ileum in Crohn's Disease: A Possible Link with Latent CMV Infection?**
KAYMAKOĞLU S., Baran B., Goksel S., Ince U., BAKIR B., Bugra D., AKYÜZ F.
Journal of Gastrointestinal Cancer, vol.45, no.1, pp.252-256, 2014 (Scopus)
- XXII. **Treatment of Hepatocellular Cancer Due to Hepatitis Delta with Yttrium-90 Radioembolization in a Patient with Cirrhosis: A Case Report**
UYANIKOĞLU A., AKYÜZ F., Ermis F., KAYMAKOĞLU S.
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, vol.20, no.3, pp.131-133, 2014 (ESCI)
- XXIII. **A rare complication of interferon treatment: optic neuropathy**
Gokturk S., Atay K., ÇİFCİBAŞI ÖRMECİ A., Baran B., Soyer O. M., AKYÜZ F., Karaca C., KAYMAKOĞLU S.
ANNALS OF GASTROENTEROLOGY, vol.24, no.4, pp.335, 2011 (ESCI)
- XXIV. **MASSIVE BLEEDING DUE TO PARACENTESIS-ACASE REPORT**
Kocabay G., Tiryaki B., Sumnu A., Gul E., KAYMAKOĞLU S.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGISİ, vol.72, no.2, pp.55-57, 2009 (ESCI)
- XXV. **Ülseratif Kolitte Cerrahi Tedavinin Hastaların Yaşam Kalitesi Üzerindeki Etkilerinin Değerlendirilmesi**
AKYÜZ N., BALIK E., KANAN N., YAMANER S., KAYMAKOĞLU S., AKYÜZ A., ÖZDİL S., BULUT M. T., BÜYÜKUNCU Y., SÖKÜCÜ N., et al.
Kolon ve Rektum Hast Derg, no.17, pp.88-101, 2007 (Peer-Reviewed Journal)

- XXVI. **Kronik Hepatit C'li hastalarda, Genotip 1b dışındaki genotiplerle enfeksiyonun, lineprobe assay 5' UTR ve NS5B bölgesinin Dizilenmesi Yöntemleri ile Araştırılması.**
KESKİN F., KAYMAKOĞLU S., Türkoğlu S.
Moleküler tanı dergisi, vol.3, no.2, pp.40-44, 2007 (Peer-Reviewed Journal)
- XXVII. **What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis?**
Demir K., Akyuz F., Ozdil S., Aksoy N., Kaymakoglu S., Poturoglu S., Akyuz U., Besisik F., Boztas G., Mungan Z., et al.
Annals of Hepatology, vol.6, no.2, pp.92-96, 2007 (Scopus)
- XXVIII. **PERNICIOUS ANEMIA ASSOCIATED WITH CRYPTOGENIC CIRRHOSIS**
Cosan F., Pinarbasi B., Ibrism D., GÜLLÜOĞLU M., DEMİR K., KAYMAKOĞLU S., Cakaloglu Y., Mungan Z.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGISI, vol.70, no.4, pp.107-110, 2007 (ESCI)
- XXIX. **Assay of Mycobacterium tuberculosis in biopsy specimens taken from hepatic granuloma patients using polymerase chain reaction method**
Tuncer İ., KÖKSALAN O. K., DEMİR K., Dinçer D., TÜRKOĞLU S., KAYMAKOĞLU S., Çevikbaş U., Badur S., Ökten A., Çakaloğlu Y.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.12, no.3, pp.189-195, 2001 (Scopus)
- XXX. **Sağlık personeli olmak HCV enfeksiyonu açısından risk faktörü mü ? Asemptomatik sağlık personelinde HCV seroprevalansı.**
Beşışık F., Ökten A., Kaymakoglu S., BADUR O. S., Yalçın S., AĞAÇFİDAN A.
Gastroenterohepatoloji, vol.3, no.3, pp.169-171, 1992 (Peer-Reviewed Journal)
- XXXI. **Türkiyede sağlıklı bireyler ve akut-NANBH olgularında hepatit E virusu antikorlarının (anti-HEV) araştırılması.**
Badur O. S., Dedeoğlu F. B., YENEN O. Ş., Yüksel D., Işık N. H., KAYMAKOĞLU S.
İNFEKSİYON DERGISİ, vol.8, no.1, pp.1-4, 1992 (Peer-Reviewed Journal)

Refereed Congress / Symposium Publications in Proceedings

- I. **ARE THERE NEW PRACTICAL MARKERS TO PREDICT MALIGNANCY IN PANCREATIC CYST FLUIDS?**
Anıl K. U., Çavuş B., Çifcibaşı Örmeci A., İmanov Z., Şenkal İ. V., Nuriyev K., İstemihan Z., Demir K., Beşışık S. F., Kaymakoglu S., et al.
Digestive Disease Week 2023, Washington, United States Of America, 6 - 09 May 2023, pp.774
- II. **Real-world data of tenofovir alafenamide in treatment-naive and experienced patients with Chronic Hepatitis B: more efficacy, less side effects**
Bektaş E., Yılmaz A., Kıkılı C. İ., Nuriyev K., İstemihan Z., Şenkal İ. V., İmanov Z., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., et al.
39. Ulusal Gastroenteroloji Haftası ve 10. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 22 - 27 November 2022, pp.1159-1162
- III. Bektaş E., Yılmaz A., Bilgin E., Mutlu Ü., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., Kaymakoglu S.
24. Ulusal İç Hastalıkları Kongresi, Antalya, Turkey, 19 - 23 October 2022, pp.136-137
- IV. **REAL-WORLD DATA OF TENOFOVIR ALAFENAMIDE IN TREATMENT-NAIVE AND EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B: MORE EFFICACY, LESS SIDE EFFECTS**
Bektaş E., Yılmaz A., Kıkılı C. İ., Nuriyev K., İstemihan Z., Şenkal İ. V., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., Demir K., et al.
AASLD Liver Meeting , District Of Columbia, United States Of America, 4 - 08 November 2022, vol.76, pp.299
- V. **İshal ve kilo kaybının nadir bir nedeni:Amiloidoz**
Çiftçi A. C., Konyaoğlu H., Şenkal İ. V., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., Demir K., Beşışık S. F., Kaymakoglu S.
21. Çapa Gastroenteroloji Günleri, İstanbul, Turkey, 31 March - 02 April 2022, pp.70
- VI. Yılmaz A., Bektaş E., Gülseren Ü. A., Şenkal İ. V., Nuriyev K., Altınkaynak M., Çavuş B., Saka B., Kaymakoglu S.
İstanbul Tıp Fakültesi Geleneksel İç Hastalıkları Günleri İnteraktif Güncelleştirme 2022, Sakarya, Turkey, 23 - 27

March 2022, pp.38-39

- VII. **Budd-Chiari Sendromu'nda Hepatoselüler Kanser ve Mortalitenin Değerlendirilmesi**
İstemihan Z., Nuriyev K., Şenkal İ. V., İmanov Z., Sarıdal M. K., Akas R., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., Demir K., et al.
38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 16 - 21 November 2021, pp.219
- VIII. **Ön Segment Optik Koherans Tomografi (OCT), Wilson hastalığı tanısında Kayser Fleischer Halkası varlığını değerlendirmek için yeri - Ehil oftalmolog gerekliliğine son verecek mi?**
Çifcibaşı Örmeci A., Bayraktar Ş., Işık A. O., İstemihan Z., Sarıdal M. K., Akas R., Çavuş B., Akyüz F., Beşişik S. F., Kaymakoglu S., et al.
38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 16 - 21 November 2021, pp.218
- IX. **TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B: WHAT ARE THE TRIGGERS OF DRUG-RELATED ADVERSE EFFECTS?**
Kapar C., Cavus B., Atasoy A., Suleymanova V., Isik A., Karahan L., Cifcibasi A. O., Akyuz F., Demir K., Besisik F., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 November 2020, vol.72
- X. **Bone health in liver transplant recipients: Corticosteroids preserve their significance, what about late follow-up?**
MİRİOĞLU Ş., ÇAKMAK DEMİR S., ILIAZ R., ÇELEN ÖGÜNÇ H., AKYÜZ F., DEMİR K., BEŞİŞİK S. F., ÖZDEN İ., KAYMAKOĞLU S.
AASLD-TASL Connect Regional Meeting, İstanbul, Turkey, 15 - 16 March 2019, vol.30, pp.21-22
- XI. **Clinical Impact of Endosonography in the Differential Diagnosis of Indeterminate Biliary Strictures**
Akyuz F., Deniz R., Karsli S., Akyuz U., Atasoy A., Demir K., Kaymakoglu S., Besisik F.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, Costa Rica, 9 - 13 November 2018, vol.68
- XII. **Is It Sufficient Only to Request an Anti-HCV Test for the Performance of HCV Screening?**
Deniz R., Karsli S., Ekinci O. B., Kalantarova I., Atasoy A., Onel M., Agacfidan A., Akyuz F., Demir K., Besisik F., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San Francisco, Costa Rica, 9 - 13 November 2018, vol.68
- XIII. **Böbrek Nakli Alıcılarında Direkt Etkili Antivirallerle HCV Tedavisi**
MİRİOĞLU Ş., İSTEMİHAN Z., ŞAHİN E., AKSOY E., DEMİR E., AKGÜL S., KAYMAKOĞLU S., YAZICI H., TÜRKMEN A., SEVER M. Ş.
34. Ulusal Nefroloji, Hipertansiyon, Diyaliz ve Transplantasyon Kongresi, Antalya, Turkey, 18 - 22 October 2017, vol.26, no.3, pp.35
- XIV. **Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?**
Akyuz F., Iliaz R., Cavus B., Atasoy A., Akyuz U., Demir K., Besisik F., Kaymakoglu S.
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 October 2017, vol.66
- XV. **Tens asitli siroz hastalarında intraabdominal hipertansiyonun prognoz üzerine etkisi**
MUTLU Ü., ATASOY A., ILIAZ R., ÇAVUŞ B., AKYÜZ F., DEMİR K., KAYMAKOĞLU S., BEŞİŞİK S. F.
11. Ulusal Hepatoloji Kongresi, Antalya, Turkey, 17 - 21 May 2017, pp.31-32
- XVI. **Vitamin D receptor gene polymorphisms may affect the interferon response in chronic hepatitis B patients**
AKYÜZ F., UÇAR A. R., ÇİFTÇİ S., KESKİN F., ILIAZ R., ÇAVUŞ B., AKYÜZ Ü., Karaca Ç., DEMİR K., BEŞİŞİK S. F., et al.
26th Annual Conference of APASL, Shanghai, China, 15 - 19 February 2017, vol.11, no.1
- XVII. **Kronik hepatit C'li hastalar artık daha yaşlı ve daha ciddi karaciğer hastalığı ile kliniğe başvuruyor**
ILIAZ R., YÜCE İNEL T., TORUN E. S., ÇAVUŞ B., GÜLLÜOĞLU M., Bozacı M., Karaca Ç., AKYÜZ F., DEMİR K., BEŞİŞİK S. F., et al.
XIII. Ulusal Viral Hepatit Kongresi, Antalya, Turkey, 17 - 20 March 2016, pp.18

- XVIII. **Olgu sunumu: İmmünokompetan hastada dissemine tüberküloz lenfadenopatisi**
DİRİM A. B., MİRİOĞLU Ş., ÇAVUŞ B., ILIAZ R., YILMAZBAYHAN E. D., AKYÜZ F., KAYMAKOĞLU S.
32. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 25 - 29 November 2015, pp.94
- XIX. **"Normal" Serum ALT/AST Level in Turkish Population**
Karasu Z., Tozun N., İDİLMAN R., ÖZDOĞAN O. C., Kaymakoglu S., Cakaloglu Y., AKARCA U. S.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62
- XX. **Hepatitis C Seropositivity is not as high as Western Countries in the Population Born Between 1945-1965 According to Turkey Nationwide Hepatitis Prevalence Study (TURKHEP 2010)**
ÖZDOĞAN O. C., Tozun N., Kaymakoglu S., İDİLMAN R., Karasu Z., AKARCA U. S.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 13 - 17 November 2015, vol.62
- XXI. **Cyclosporine Therapy As a Rescue Treatment in Acute Severe Ulcerative Colitis: A Real Life-Data From a Tertiary Center**
Evirgen S., Iliaz R., AKYÜZ F., ÇAVUŞ B., Pinarbasi B. S., Karaca C., DEMİR K., Besisik F., KAYMAKOĞLU S.
46th Annual Digestive Disease Week (DDW), Washington, Kiribati, 16 - 19 May 2015, vol.148
- XXII. **Hasta ortada kalmasın Multidisipliner yaklaşım**
TÜKEK T., TANAKOL R., KAYMAKOĞLU S., YENEREL M. N., KÖSE M.
"Geleneksel İç Hastalıkları Günleri-İnteraktif Güncelleştirme - 2016", Turkey, 11 - 13 March 2015
- XXIII. **Chronic Renal Failure after Liver Transplantation in Long Term: Prevalence and Risk Factors.**
Gokturk S., Baran B., Ormeci A., Soyer O., Evirgen S., Ozden I., Akyuz F., Karaca C., Demir K., Kaymakoglu S., et al.
Joint International Congress of ILTS, ELITA and LICAGE, London, Canada, 4 - 07 June 2014, vol.20
- XXIV. **The Course of Pregnancy in Wilson's Disease-One Center, 20 Years' Experience**
DEMİR K., Soyer O. M., Karaca C., BEŞİŞİK S. F., KAYMAKOĞLU S., BEŞİŞİK S. F.
55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW), Illinois, United States Of America, 3 - 06 May 2014, vol.146
- XXV. **Baseline alfa-fetoprotein level is a strong predictor of vascular invasion and survival in patients with hepatocellular carcinoma**
Ekinci O., Baran B., Ormeci A., Soyer O. M., Gokturk S., Poyanli A., Gulluoglu M., Karaca C., Akyuz F., Demir K., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58
- XXVI. **The antiviral efficacy of entecavir is not influenced by prior treatment with nucleos(t)ide analogues in patients with chronic hepatitis B**
Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., Karaca C., Demir K., Besisik F., Onel D., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013
- XXVII. **Virological Suppression Does not Prevent the Development of Hepatocellular Carcinoma in Cirrhotic Patients with Genotype D Hepatitis B Infection**
Gokturk S., Basar R., Ucar A. R., Basgoze B. H., Altinkaynak M., Buyukballi P., Alpaslan B., Baran B., Ormeci A., Soyer O. M., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58
- XXVIII. **Risk factors for significant liver fibrosis in genotype D HBeAg-negative chronic hepatitis B infection with persistently normal ALT and high serum HBVDNA levels**
Ormeci A., Akyuz F., Baran B., Soyer O. M., Gokturk S., Karaca C., Gulluoglu M., Onel D., Badur S., Demir K., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013
- XXIX. **Tenofovir disoproxil fumarate has a substantial efficacy against adefovir and multi-drug resistant strains of hepatitis B virus**
Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., Karaca C., Demir K., Besisik F., Onel D., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases,

Washington, Kiribati, 1 - 05 November 2013

- XXX. **Safety of Tenofovir in Renal Transplanted and Hemodialysis Patients with Chronic Hepatitis B**
Akyuz F., Gokturk S., Baran B., Ormeci A., Soyer O. M., Evirgen S., Karaca C., Demir K., Besisik F., Kaymakoglu S.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases,
Washington, Kiribati, 1 - 05 November 2013, vol.58
- XXXI. **Does Chemoprophylaxis Prevent Tuberculosis Reactivation in the Long Term Period of Anti-TNF Treatment?**
AKYÜZ F., Soyer O. M., Gokturk S., ÇİFCİBAŞI ÖRMECİ A., Evirgen S., Onder S. Y., Karaca C., DEMİR K., BEŞİŞİK S. F., KAYMAKOĞLU S.
Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Florida, United States Of America, 18 - 21 May 2013, vol.144
- XXXII. **Response to tenofovir treatment of treatment-naive and adefovir experienced patients with chronic hepatitis b**
KESKİN O., Ormeci A., Kabacam G., Akyuz F., Aniktar H., Karaca C., İDİLMAN R., Kaymakoglu S., Yurdaydin C.
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 9 - 13 November 2012, vol.56
- XXXIII. **Number connection test-A and inhibitor control test are not efficient for diagnosis of minimal hepatic encephalopathy in cirrhotic patients**
Baran B., Ozcan E., Oztop N., Cakmak R., Soyer O. M., Ormeci A., Gokturk S., Karaca C., Akyuz F., Demir K., et al.
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 9 - 13 November 2012, vol.56
- XXXIV. **Investigation of resistance mutations in the HBV DNA samples that isolated from patients with chronic Hepatitis nucleoside/nucleotide analogues by INNO-LIPA HBV DR and ultradeep pyrosequencing methods**
MEŞE S., ARIKAN M., ÇAKİRİS A., ABACI N., ÖNEL D., USTEK D., KAYMAKOĞLU S., Badur S., YENEN O. Ş., BOZKAYA E.
2nd World Congress on Virology, Las Vegas, United States Of America, 20 - 22 August 2012, vol.4, no.4, pp.147
- XXXV. **Success of Two Different Endoscopic Submucosal Resection Methods in Gastric Subepithelial Lesions**
Karaca C., Soyer O. M., Akyuz F., Baran B., Ormeci A., Gokturk S., Demir K., Ozdil S., Besisik F., Kaymakoglu S.
Digestive Disease Week (DDW), California, United States Of America, 19 - 22 May 2012, vol.75, pp.136
- XXXVI. **ANTIVIRAL RESISTANCE IN NAIVE GENOTYPE D CHRONIC HEPATITIS B PATIENTS BY ULTRA-DEEP PYROSEQUENCING**
Akyuz F., Ciftci S., Keskin F., Pinarbasi B., Baran B., Ustek D., Kaymakoglu S.
62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Costa Rica, 4 - 08 November 2011, vol.54
- XXXVII. **A NATIONWIDE PREVALENCE STUDY AND RISK FACTORS FOR HEPATITIS A, B, C AND D INFECTIONS IN TURKEY**
Tozun N., ÖZDOĞAN O. C., Cakaloglu Y., İDİLMAN R., Karasu Z., AKARCA U. S., Kaymakoglu S., Ergonul O.
61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 29 October - 02 November 2010, vol.52
- XXXVIII. **CLEVUDINE TREATMENT OF CHRONIC DELTA HEPATITIS**
Yakut M., Seven G., Baran B., Kabacam G., Karatayli E., BOZDAYI A. M., Idil-man R., Kaymakoglu S., Yurdaydin C.
61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 29 October - 02 November 2010, vol.52
- XXXIX. **CLONAL ANALYSIS OF THE QUASISPECIES OF ANTIVIRAL RESISTANT HBV GENOMES IN PATIENTS WITH ENTECAVIR RESISTANCE TREATED WITH RESCUE LAMIVUDINE-ADEFOVIR COMBINATION THERAPY**
Karatayli E., İDİLMAN R., Karatayli S. C., Cevik E., AKARCA U. S., Kaymakoglu S., BOZDAYI A. M., Yurdaydin C.
60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 30 October - 03 November 2009, vol.50
- XL. **Ultra-Deep Pyrosequencing (UDPS) yöntemi ile naiv kronik B hepatitli hastalarda antiviral direnç araştırılması.**

AKYÜZ F., ÇİFTÇİ S., KESKİN F., PINARBASI B., ÇAKIRİS A., ABACI N., Badur O. S., USTEK D., KAYMAKOĞLU S.
26. Ulusal Gastroenteroloji Haftası, Ankara, Turkey, 14 - 18 October 2008, pp.206

- XLII. **A new agent for tumour necrosis factor-alpha inhibition: In vitro effects of dipyridamole in Crohn's disease**
Poturoglu S., KAYMAKOĞLU S., polat N. G., Ibrism D., Ahishali E., AKYÜZ F., Badur S., DEMİR K., Mungan Z. A.
Digestive Disease Weeking Meeting/ASGE Postgraduate Course Meeting, Washington, Kiribati, 19 - 24 May 2007, vol.132
- XLII. **Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naive HBeAg(+) patients (ETV 022/901)**
Chang T., Chao Y., Kaymakoglu S., Cheinquer H., Pessoa M., Gish R., Poordad F., Yang J., Brett-Smith H., Hindes R.
57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Massachusetts, United States Of America, 27 - 31 October 2006, vol.44
- XLIII. **A multicenter, randomized, prospective study of 14 days ranitidine bismuth citrate vs. lansoprazole based triple therapies for the eradication of Helicobacter pylori in dyspeptic patients.**
Avsar E., KAYMAKOĞLU S., Erzin Y., Poturoglu S., Dincer D., Tiftikci A., Yildirim B., Guliter S., Turkyay C., Onuk M., et al.
Annual Meeting of the American-Gastroenterological-Association/Digestive-Disease-Week, Illinois, United States Of America, 14 - 19 May 2005, vol.128
- XLIV. **Combined or monotherapy, which is better in AntiHBe (+) chronic hepatitis B ?**
Danalioglu A., KAYMAKOĞLU S., Cakaloglu Y., DEMİR K., AKYÜZ F., Aksoy N., Poturoglu S., Turkoglu S., Badur S., Besisik F., et al.
Digestive Disease Week 2003 Meeting/104th Annual Meeting of the American-Gastroenterological-Association, ORLANDO, FLORIDA, 17 - 22 May 2003, vol.124

Supported Projects

KAYMAKOĞLU S., Project Supported by Higher Education Institutions, Kronik hepatit B`de tedaviye yanıtızlıđın belirlenmesinde virusa ait genetik deđiřikliklerin rolü, 2010 - 2011

Metrics

Publication: 186

Citation (WoS): 1855

Citation (Scopus): 4105

H-Index (WoS): 18

H-Index (Scopus): 22

Non Academic Experience

İ.Ü.İstanbul Tıp Fakültesi